202272-68-2

Basic information

• Product Name: GW2974
• Synonyms: N~4~-(1-Benzyl-1H-indazol-5-yl)-N~6~,N~6~-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine; pyrido[3,4-d]pyrimidine-4,6-diamine, N~6~,N~6~-dimethyl-N~4~-[1-(phenylmethyl)-1H-indazol-5-yl]-
• CAS NO: 202272-68-2
• Molecular Formula: C23H21N7
• Molecular Weight: 395.468
• Mol File: 202272-68-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 645.6°C at 760 mmHg
• Flash Point: 344.3°C
• Appearance: yellow/
• Density: 1.3g/cm³
• Vapor Pressure: 1.47E-16mmHg at 25°C
• Refractive Index: 1.71
• Solubility: DMSO: ≥20mg/mL
• CAS DataBase Reference: GW2974(CAS DataBase Reference)
• NIST Chemistry Reference: GW2974(202272-68-2)
• EPA Substance Registry System: GW2974(202272-68-2)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 202272-68-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C23H21N7/c1-29(2)22-11-19-20(13-24-22)25-15-26-23(19)28-18-8-9-21-17(10-18)12-27-30(21)14-16-6-4-3-5-7-16/h3-13,15H,14H2,1-2H3,(H,25,26,28)

Upstream product

• 171178-46-4 5-[N-(tert-butoxycarbonyl)amino]-2-chloropyridine-4-carboxylic acid 
• 171178-45-3 tert-butyl (6-chloropyridin-3-yl)carbamate 
• 58483-95-7 5‐amino‐2‐chloropyridine‐4‐carboxylic acid 
• 171178-48-6 4,6-dichloro-pyrido<3,4-d>pyrimidine 
• 171178-47-5 6-chloro-3H-pyrido[3,4-d]pyrimidin-4-one 
• 100-39-0 benzyl bromide 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 189680-99-7 4-chloro-6-(N,N-dimethylamino)-pyrido[3,4-d]pyrimidine 
• 23856-21-5 1-benzyl-1H-indazol-5-ylamine 
• 124-40-3 dimethyl amine 
• 202272-67-1 (1-benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine 
• 23856-20-4 5-nitro-1-(phenylmethyl)-1H-indazole 
• 189680-98-6 6-dimethylamino-3H-pyrido[3,4-d]pyrimidin-4-one 
• 5401-94-5 5-nitroindazole 

Relevant articles and documents

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Described herein is the design and synthesis of indazolylaminopyridopyrimidines and quinazolines as inhibitors of the class 1 tyrosine kinase receptor family. Data is presented for N4-(1-benzyl-1H-indazol-5-yl)-N6,N6- dime